Sonali Gupta, Pooja Agarwal, Kalgi D. Baxi, Abhishek Nyati
{"title":"咪喹莫特：一种老药的新视角","authors":"Sonali Gupta, Pooja Agarwal, Kalgi D. Baxi, Abhishek Nyati","doi":"10.25259/ijpgd_99_2023","DOIUrl":null,"url":null,"abstract":"Imiquimod is a topical age-old drug belonging to the imidazoquinolones class which acts by modulating the immune system. It has been approved by the US Food and Drug Administration for treating external genital and perianal warts, actinic keratoses and superficial basal cell carcinoma. Along with these, there have been a large number of diseases for which the drug has played a beneficial role with a good safety profile.","PeriodicalId":339918,"journal":{"name":"Indian Journal of Postgraduate Dermatology","volume":"56 31","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Imiquimod: Newer Perspectives to an Old Drug\",\"authors\":\"Sonali Gupta, Pooja Agarwal, Kalgi D. Baxi, Abhishek Nyati\",\"doi\":\"10.25259/ijpgd_99_2023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Imiquimod is a topical age-old drug belonging to the imidazoquinolones class which acts by modulating the immune system. It has been approved by the US Food and Drug Administration for treating external genital and perianal warts, actinic keratoses and superficial basal cell carcinoma. Along with these, there have been a large number of diseases for which the drug has played a beneficial role with a good safety profile.\",\"PeriodicalId\":339918,\"journal\":{\"name\":\"Indian Journal of Postgraduate Dermatology\",\"volume\":\"56 31\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Postgraduate Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25259/ijpgd_99_2023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Postgraduate Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/ijpgd_99_2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Imiquimod is a topical age-old drug belonging to the imidazoquinolones class which acts by modulating the immune system. It has been approved by the US Food and Drug Administration for treating external genital and perianal warts, actinic keratoses and superficial basal cell carcinoma. Along with these, there have been a large number of diseases for which the drug has played a beneficial role with a good safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
